Led · Series F · Nov 2025

Founded in 2014, TimeTree develops and operates the social calendar application “TimeTree,” allowing groups and individuals to share and coordinate schedules in real time. The service has accumulated over 67 million registered users and hosts more than 13 billion saved events, giving the company a sizable proprietary data asset. Management plans to leverage this data to build new AI-driven features and to accelerate international growth, beginning with the January 2025 launch of its first overseas subsidiary, TimeTree Korea. The company will also invest in marketing across Japan and broader Asia while strengthening hiring and internal organization. To date, TimeTree has raised a cumulative ¥6.7 billion in primary capital. The newly announced funds will specifically support AI feature development, overseas market penetration, and talent acquisition.

Participated · Seed · Apr 2025

RLWRLD is a physical AI company building robotics intelligence that collects and learns from on-site industrial data, enabling robots to understand their environments and make autonomous decisions. After completing initial technology verification, the firm is now running joint proof-of-concept (PoC) and RX (robotic transformation) projects with major Korean companies such as CJ Logistics and Lotte, and is expanding trials in Japan through partner Z Venture. Management states that real-world validation is critical and plans to officially release a robotics foundation model in the first half of 2026. Demand for its technology is rising amid East Asia’s labor shortages, driving interest from strategic partners that control large industrial sites. Financially, RLWRLD secured about US$15 million in a Seed 1 round and has now added roughly US$26 million in Seed 2 financing, bringing cumulative seed funding to approximately US$41 million. The fresh capital supports continued product development and broader global collaborations. Key backers include Headline Asia, CJ Logistics Corporation, Kakao Investment, LOTTE Ventures, Hanwha Asset Management, Mirae Asset·emart and Z Venture.

Participated · Equity · Dec 2024

TwelveLabs develops foundational video models and an end-to-end video cognition platform that converts raw video into structured, searchable intelligence. Its Marengo 3.0 model provides advanced video embeddings and its Pegasus 1.5 model extracts structured scene boundaries, entities, and temporal segments; both models are distributed via TwelveLabs’ API and Amazon Bedrock. The company has begun moving beyond models into a full-stack agentic architecture that maintains persistent, compoundable memory of indexed video and ships application-layer products such as Rodeo. TwelveLabs counts customers and traction in media and entertainment and is expanding into government and other verticals including advertising, security, sports, and automotive. It operates R&D in San Francisco and Seoul and plans geographic expansion with new offices in New York and London. The company also maintains a strategic partnership with AWS, including optimization on Trainium chips and prioritized model launches on AWS.

Participated · Series A · Dec 2023

ImpriMed develops AI-powered live-cell drug sensitivity and predictive models to identify effective anticancer medicines for individual canine and feline blood cancers. Its core service measures live tumor-cell responses in a California lab and combines those measurements with biological data to produce a treatment report delivered to veterinarians within seven days. Veterinary services are fully commercialized (five canine and three feline services), generate revenue, and have been used by more than 350 U.S. veterinarians; the company says it has helped over 5,000 dogs with lymphoma and collected outcome follow-up on over half of those cases. ImpriMed has run validation work with data from 2,000 human blood-cancer patients and the Mayo Clinic Platform’s 3 million‑patient database. The company plans to expand its veterinary-to-human precision oncology efforts, with an AI multiple myeloma product targeting commercialization in 2025 and plans to commercialize services for human AML and non-Hodgkin’s lymphoma before the end of 2024. It also offers a live-cell CRO service to help drug developers measure compound efficacy on patient cells. The startup plans to use new funding to expand its drug-response prediction technology into human oncology, grow its team (about 40 staff) and broaden business-development pipelines. ImpriMed is a Palo Alto-based veterinary precision medicine company that uses artificial intelligence to predict which anti-cancer drugs are most likely to be effective for a particular dog’s lymphoma or leukemia. It generates live data from chemosensitivity and immunophenotyping assays on patients’ fresh cancer cells to produce quantified drug response predictions for veterinary oncologists. Led by CEO and co‑founder Dr. Sungwon Lim, the company enables clinicians to make chemotherapy decisions with greater confidence prior to drug administration. To date ImpriMed has provided more than 2,000 services to community-treated canine patients. The company plans to use the new funding to develop additional prediction models for its current canine blood-cancer targets, scale up its customer network and expand pipelines to other types of cancers in dogs and cats. Financially, ImpriMed closed an $8m Pre-Series A round comprising $7.7m from venture capital investors and the remainder as a government grant. ImpriMed uses precision medicine techniques to test hundreds of drug responses on fresh biopsy samples from canine cancer patients, observing how live cancer cells react before treatment. The platform screens for the most effective chemotherapy options and excludes non-effective ones, then provides those results to veterinary oncologists. The company is currently focused on treating lymphoma in dogs. ImpriMed plans to roll out a clinical trial that will be performed primarily at SAGE Veterinary Centers in the Bay Area. For a limited time it is offering its service free of charge while completing the clinical trial and aims to help more than 500 dogs by 2020. The company was founded in 2017 and maintains an additional presence in Seoul, South Korea.

Participated · Series B · Dec 2023

Allganize provides enterprise LLM solutions including the Alli LLM App Market, the Alli AI chatbot, and Alli for Invoice to help companies automate and optimize workflows. The Alli LLM App Market offers 100+ ready-to-use LLM apps and no-code app creation, with multi-LLM support (GPT-4, GPT-3.5, Llama2, PaLM2) and options for sLLMs and on-premise deployment. The Alli chatbot delivers high response accuracy, document-based QA extraction, external tool integrations, and is offered from ¥100,000 per month. Alli for Invoice extracts data from non-standard invoices without complex setup and supports required invoice items for Japan’s invoicing system. Allganize plans to further advance its AI solutions, accelerate global expansion focused on Japan, the U.S., and Korea, and aggressively hire AI talent. The company was founded in 2017 and operates from Tokyo, Houston, and Seoul; it recently raised $20.2M in a Series B to support product development and international growth. Allganize develops NLP technology that extracts answers to natural-language questions directly from millions of unstructured text documents without manual preparation of training data. The platform can also automatically generate questions and answers from unstructured data. Led by founder and CEO Changsu Lee and based in San Francisco, the company has acquired over 100 enterprise customers in the US, Japan, and Korea, including SMBC, Persol, Kao, JPower, KB Securities, Hyundai Card, and Smilegate. In August 2021 it raised $10M in a round led by Atinum Investment with participation from Stonebridge Ventures, Sumitomo Mitsui Banking Corporation and existing investors, bringing total funds raised to $15M since its July 2017 founding. The company plans to use the proceeds to accelerate research and development, expand globally, and increase headcount in 2021. Allganize develops deep learning–based natural-language understanding (NLU) and conversational AI for enterprise customers. Its Alli.ai conversational AI and chatbot service aims to deliver highly personalized customer experiences by recognizing complex named entities and user intents from chat and voice data. The company leverages proprietary high-performance NLU technology to help companies build their own AI systems and services. Allganize has demonstrated market traction, securing business with Persol Process and Technology in Japan. The company intends to use the Series A proceeds to accelerate distribution of its solution to businesses. It operates from offices in Oakland, Seoul (Gangnam-daero, Gangnam-gu), and Tokyo.